Today: 5 March 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

New Gold Inc (NGD) Stock: 201% Rally, $7 Billion Coeur Mining Buyout and December 2025 Analyst Outlook

New Gold Inc (NGD) Stock: 201% Rally, $7 Billion Coeur Mining Buyout and December 2025 Analyst Outlook

New Gold Inc. shares surged 201% over the past year, trading near C$11.37 on the TSX and US$7.80 on NYSE American as of December 11, 2025. The company posted record Q3 free cash flow of US$205 million and agreed to a $7 billion all-stock takeover by Coeur Mining. New Gold’s market cap stands at roughly US$6.2 billion, with analysts issuing unusually bullish “Buy” ratings.
11 December 2025
·····
Hecla Mining (HL) Stock Hits 52‑Week High as Silver Soars: December 2025 Outlook, Forecasts and Risks

Hecla Mining (HL) Stock Hits 52‑Week High as Silver Soars: December 2025 Outlook, Forecasts and Risks

Hecla Mining stock hit a 52-week high of $18.13 on December 11, 2025, capping a year-to-date gain of over 200%. The company’s market value now stands near $12 billion, as shares far outpaced silver prices and the broader market. Analysts remain divided, with most forecasts below the current price. Hecla operates major silver and gold mines in Alaska, Idaho, Quebec, and Yukon.
11 December 2025
··
Polestar Automotive (PSNY) Stock Plunges After Reverse Split – Latest News, Analyst Forecasts and 2025–2026 Outlook

Polestar Automotive (PSNY) Stock Plunges After Reverse Split – Latest News, Analyst Forecasts and 2025–2026 Outlook

Polestar shares plunged over 20% Wednesday and slid further Thursday, trading near $12.45 after a 1-for-30 reverse stock split and a Nasdaq compliance warning. The stock hit a new 52-week low despite reporting nearly 50% revenue growth for 2025 so far. Technical analysts now rate PSNY a “Strong Sell,” projecting up to 46% more downside in the next three months.
11 December 2025
·
Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences shares surged over 180% in a week after Phase 1 data showed its obesity drug WVE-007 reduced visceral fat by up to 10% and increased lean mass. The stock hit a five-year high near $22 before retreating to $17.06 following a $350 million equity offering and insider selling. Analyst price targets jumped, but Wave remains unprofitable with high valuation risk.
11 December 2025
···
Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio shares surged nearly 200% year-to-date, trading around $7.84 on December 11, 2025, after FDA approval of its lung cancer drug IBTROZI and strong analyst upgrades. H.C. Wainwright raised its price target to $18, citing higher revenue forecasts and clinical results. Average daily volume reached 8.7 million shares. The company reported 204 new patients started IBTROZI in Q3.
11 December 2025
First Majestic Silver (AG) Blasts to a 52‑Week High as Silver Hits Records – Can the Run Last?

First Majestic Silver (AG) Blasts to a 52‑Week High as Silver Hits Records – Can the Run Last?

First Majestic Silver shares hit a 52-week high of $16.30 on December 11, trading near $16.50 intraday, after silver prices reached all-time highs. The stock is up about 185–190% year-to-date, lifting market cap to $7.5–8.0 billion. Q3 2025 saw record silver production of 3.9 million ounces and EBITDA of $128.6 million. Net earnings reached $43 million, reversing a loss from last year.
11 December 2025
···
Centene (CNC) Stock Jumps on Baird Upgrade: What December 11, 2025 Means for the Outlook and Forecasts

Centene (CNC) Stock Jumps on Baird Upgrade: What December 11, 2025 Means for the Outlook and Forecasts

Centene shares jumped above $40 on December 11, 2025, after Baird raised its price target to $36 but kept a neutral rating. The stock closed at $40.73, up 5.3%, extending a rebound from a summer marked by guidance cuts and a rare loss. CNC now trades about 62% above its 52-week low but remains 39% below its February high. The price is at or above most analyst targets, with consensus ratings still cautious.
11 December 2025
·
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics shares traded near $46 on December 11, 2025, after announcing a $261 million stock offering at $42.50 per share. The company filed a Biologics License Application for atacicept in IgA nephropathy and reported strong late-stage clinical results. Shares are up nearly 100% in six months, with market cap around $2.9–3.0 billion. The offering is expected to close today.
11 December 2025
·
Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals shares surged to a new 52-week high above $72 on December 11 after the FDA approved its first drug, Redemplo, for familial chylomicronemia syndrome. The stock has climbed from the low-$40s to around $70 in a month, pushing market value to $9.6 billion, up over 300% year-over-year. The company also received an FDA Breakthrough Therapy designation and launched its first Alzheimer’s trial.
11 December 2025
··
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant shares rose 9% to $25.75 Thursday after the company announced a $550 million common stock offering to fund development and possible launch of its lead drug, IMVT‑1402, for Graves’ disease. The offering priced at $21 per share, an 11% discount, and is expected to close December 12. Roivant Sciences will participate. Immunovant’s market value reached about $4 billion.
11 December 2025
····
Coeur Mining (CDE) Stock on December 11, 2025: Palmarejo Breakthroughs, $7B New Gold Deal and What Comes Next

Coeur Mining (CDE) Stock on December 11, 2025: Palmarejo Breakthroughs, $7B New Gold Deal and What Comes Next

Coeur Mining shares traded around $16.84 on December 11, up 5% intraday, with volume over 6 million. The company announced a $7 billion all-stock deal to acquire New Gold Inc. and posted record Q3 revenue of $555 million and net income of $267 million. CDE’s market value has surged to about $10 billion after a rally from a 52-week low of $4.58 to a high near $23.61.
11 December 2025
···
Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio shares climbed to $154 on December 11, 2025, up over 130% year-to-date, after announcing positive Phase 3 results for tinlarebant in Stargardt disease. The company’s market value reached $5–6 billion. The DRAGON trial showed tinlarebant cut lesion growth by 36% versus placebo in adolescents with STGD1. Wall Street analysts project further upside for the stock.
11 December 2025
·
Wayfair (W) Stock Nears $100 as Hedge Funds Buy and Jefferies Turns Cautious – December 11, 2025 Outlook & Forecast

Wayfair (W) Stock Nears $100 as Hedge Funds Buy and Jefferies Turns Cautious – December 11, 2025 Outlook & Forecast

Wayfair shares rose about 7% Thursday to near $100, following a volatile year that saw the stock rally over 100% year to date but fall 17% in the past month. The stock remains nearly 19% below its November high. Hedge funds, including Mane Global Capital, disclosed new stakes, while short interest hovers near 15%. Insiders have been selling as analysts remain split on the outlook.
11 December 2025
··
Unity Software (NYSE: U) Stock Outlook: Analyst Upgrades, Q3 Beat and 2026 Forecasts Fuel a High‑Beta Rally

Unity Software (NYSE: U) Stock Outlook: Analyst Upgrades, Q3 Beat and 2026 Forecasts Fuel a High‑Beta Rally

Unity Software shares traded near $51 on December 11, close to a 52-week high, valuing the company at about $22 billion. The stock has rebounded roughly 90% over the past year, outpacing the S&P 500, but remains below its 2020 IPO price. Q3 2025 revenue rose 5% to $471 million, with adjusted EPS of $0.20 and free cash flow of $151 million. GAAP net loss for the quarter was $127 million.
11 December 2025
Upwork (UPWK) Stock Hits Fresh 52‑Week High: AI Partnerships, Index Inclusion and Q3 Earnings Rewire the 2026 Outlook

Upwork (UPWK) Stock Hits Fresh 52‑Week High: AI Partnerships, Index Inclusion and Q3 Earnings Rewire the 2026 Outlook

Upwork shares hit a new 52-week high of $21.39 on December 11, 2025, lifting its market cap to about $2.46 billion. The stock is up nearly 90% from its yearly low, driven by record Q3 results, new AI partnerships, and entry into the S&P SmallCap 600. Insider selling and high short interest remain. Upwork now posts positive GAAP earnings and a gross margin near 78%.
11 December 2025
····
Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences shares climbed near $21.50 on December 11, approaching 52-week highs after the company’s Investor Day outlined plans for at least three product launches and four regulatory filings by 2028. The stock has gained about 85% over six months, pushing market value to roughly $15 billion. Management advanced timelines for key drug programs, including brepocitinib and IMVT-1402.
11 December 2025
Brinker International (EAT) Stock: Fresh News, Analyst Forecasts and Turnaround Outlook as of December 11, 2025

Brinker International (EAT) Stock: Fresh News, Analyst Forecasts and Turnaround Outlook as of December 11, 2025

Brinker International shares rose 7% to $146 intraday on December 11, 2025, after outperforming short-term trading models and drawing institutional interest. The stock remains 24% below its 52-week high and 46% above its low. Chili’s same-store sales have grown by high teens to low 20% in recent quarters, driving improved margins and over $500 million in debt reduction.
11 December 2025
··
Lemonade (LMND) Stock Soars to 52-Week High on Tesla Integration and Q3 2025 Beat: Is the Rally Sustainable?

Lemonade (LMND) Stock Soars to 52-Week High on Tesla Integration and Q3 2025 Beat: Is the Rally Sustainable?

Lemonade shares traded near $82 on December 11, 2025, after hitting a 52-week high above $84.50, up from a low near $24. The company’s market cap has more than doubled to about $6 billion in the past year. Lemonade’s price-to-sales ratio stands near 9x, far above traditional insurers. Q3 revenue rose 42% year-over-year to about $195 million.
11 December 2025
····
1 … 479 480 481 482 483 … 584
Go toTop